Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

636

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

October 31, 2009

Conditions
OverweightObesity
Interventions
DRUG

pramlintide acetate

subcutaneous injection, twice a day

DRUG

metreleptin

subcutaneous injection, twice a day

DRUG

placebo-P

subcutaneous injection, twice a day

DRUG

placebo-M

subcutaneous injection, twice a day

Trial Locations (36)

Unknown

Research Site, Birmingham

Research Site, Chandler

Research Site, Santa Rosa

Research Site, Walnut Creek

Research Site, Denver

Research Site, Jacksonville

Research Site, Miami

Research Site, Pembrook Pines

Research Site, Plantation

Research Site, Atlanta

Research Site, Chicago

Research Site, Springfield

Research Site, Overland Park

Research Site, Baton Rouge

Research Site, Auburn

Research Site, Boston

Research Site, Edina

Research Site, St Louis

Research Site, Butte

Research Site, New York

Research Site, Statesville

Research Site, Cincinnati

Research Site, Columbus

Research Site, Eugene

Research Site, Medford

Research Site, Anderson

Research Site, Greer

Research Site, Mt. Pleasant

Research Site, Nashville

Research Site, Austin

Research Site, Dallas

Research Site, San Antonio

Research Site, Salt Lake City

Research Site, Norfolk

Research Site, Belingham

Research Site, Olympia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY